Fusion Pharmaceuticals is a clinical-stage company focused on developing next-generation radiopharmaceuticals as precision medicines to treat cancer.

The company now trades on NASDAQ: FUSN, following its June 2020 IPO.

Alan O Connell.

Managed by

Alan O'Connell


We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top